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Introduction: JNJ-26489112 appeared in animal models as a cen-
trally active, broad spectrum anticonvulsant. A Phase-IIa placebo-
controlled, single-blind Proof of Concept study was performed to 
explore dose-related anticonvulsant effects in epilepsy patients.
Patients (or Materials) and Methods: Twelve adult Caucasian 
patients (3 men, 9 women; age, 18–40) with idiopathic photosensi-
tive epilepsy underwent standardized photic stimulation during scalp 
EEG recording. Photosensitivity ranges (SPR) were determined before 
and at hourly intervals for up to 8 hours and at 12 hours after receiv-
ing a single oral dose of placebo on day 1, JNJ-26489112 on day 
2, and a second dose of placebo on day 3. One patient withdrew 
after day 1. A positive response was defined as abolishment of the 
epileptogenic response or reduction in at least 3 out of 4 consecu-
tive time points on either day 2 or day 3 compared with baseline 
day 1. The difference in SPR at each time point on day 2 and day 3 
were calculated relative to matched time points on day 1 and plot-
ted versus time for each patient. The type of response (ie, positive 
response or complete suppression) and number of responders were 
summarized by dose level. Cohorts of 4 patients were dosed 1000, 
2000, or 3000 mg, respectively, and blood samples taken after each 
EEG photosensitivity measure. Safety was assessed by the reporting 
of adverse events, vital signs, 12-lead ECG, physical and neurological 
examinations, and laboratory assessments.
Results: Ten of 11 patients (91%) showed a clear pharmacodynamic 
effect starting on dosing day 2, with a dose-dependency for complete 
suppression.The median Tmax of JNJ-26489112 (range, 3.73–5.04 
hours) in plasma was similar across all 3 dose groups and plasma 
exposure increased proportionally with dose; concentrations of 
other AEDs did not appear to be effected by coadministration of 
JNJ-26489112. Most frequent adverse events reported being mild 
headache, dizziness, and nausea.
Conclusion: Single oral doses of JNJ-26489112 were well tolerated 
and exhibited dose-related antiepileptic effects in patients with idi-
opathic, photosensitive epilepsy.
Disclosure of Interest: D. Kasteleijn-Nolst Trenité: Grant/research 
support from UCB pharma, consultant for Johnson and Johnson, 
UCB Pharma, Upsher Smith, Icagen, and Neurotherapeutics. N. 
Diprospero: None declared. J. Moyer: None declared. J. Gambale: 
None declared. G. Pandina: None declared. L. Ford: None declared. 
S. Girgis: None declared. L. Xi: None declared. J. Nye: None 
declared.
PP166—EffECT of CarVEDilol VErSuS 
CarVEDilol/iVabraDiNE CombiNaTioN oN 
HEarT raTE, QualiTy of lifE, morbiDiTy 
aND morTaliTy iN PaTiENTS wiTH STablE 
iSCHEmiC HEarT failurE
T. Al Saadi1; M. Sallam2; K. Al Hashmi3; and A.M. Elhawary1*
1Phamacology and Clinical Pharmacy, College of Medicine and 
Health Sciences, Sultan Qaboos University; 2Cardiology, Sultan 
Qaboos University Hospital; and 3Physiology, College of Medicine 
and Health Sciences, Sultan Qaboos University, muscat, Oman
Introduction: Increased heart rate is a significant predictor of death 
and hospitalization in heart failure patients. Risk increases directly 
with increasing heart rate above 60 beats/min. These lead to the 
hypothesis that lowering heart rate with the If inhibitor, ivabradine, 
could be beneficial for cardiac function and clinical outcomes in heart 
failure patients.
Patients (or Materials) and Methods: A total of 309 stable IHF 
patients attending Sultan Qaboos University Hospital, Cardiology 
Clinic, were screened. Qualified patients were enrolled in the study 
and were randomly allocated to 2 groups: carvedilol up to 25 mg BID 
(group I) and carvedilol/ivabradine up to 25/7.5 mg BID (group II). 
The duration of follow-up was 6 months. The average daily dose of 
ivabradine was 5.8 mg. The average daily dose of carvedilol was 16.2 
mg and 11.4 mg in group I and in group II respectively.
Results: Resting HR decreased in both groups from 82.6 (12) to 
72.9 (12.7) beats/min in group 1 (P = 0.05); and from 85.3 (9.7) to 
68.5 (9.4) beats/min in group II (P = 0.05). The reduction in HR was 
significantly higher in the combination group [(diff = 7.3 beats/min, P 
= 0.03)]. There was a significant increment in left ventricular ejection 
fraction (LVEF) in group II by 4.6 (5.9)% (P = 0.01), whereas no 
significant change was observed in group I. The reduction in HR due 
to ivabradine was associated with pronounced increment in health-
related quality of life and reduction of incidence of admission events 
to hospital with worsening heart failure. Ivabradine in combination 
with carvedilol was associated with nonsignificant asymptomatic 
bradycardia (P = 0.08).
Conclusion: Combining ivabradine to carvedilol in stable ischemic 
heart failure patients with heart rate faster than 70 beats/min was 
associated with better heart rate reduction, improvement of quality 
of life, and reduced rehospitalization. Risk of bradycardia should 
be taken in consideration when ivabradine is used with carvedilol
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Introduction: Combining the regulatory requirement to obtain 
human mass balance and metabolism data along with determin-
ing absolute oral bioavailability and clearance data for new drugs 
requires an ability to formulate and manufacture both intravenous 
and oral drug products at microtracer and therapeutic doses, respec-
tively, along with the ability to correctly implement accelerator mass 
spectrometry (AMS) to provide the differential analysis required for 
14C intravenous drug product.
Patients (or Materials) and Methods: We will describe variations of 
integrated study design, combining intravenous microtracer doses 
with the conventional human mass balance study either as a crossover 
study in the same subjects or as a parallel group study in separate 
cohorts of subjects to deliver a material, time and cost efficient study 
that is rich in PK and metabolism data to support regulatory sub-
mission. In the microtracer part of the study, intravenous levels of 
14C parent drug are generated by AMS analysis and absolute bio-
availability data is generated by comparison against conventional 
liquid chromatography-mass spectrometry (LC-MS/MS) analysis of 
unlabeled orally administered drug. Mass balance data are generated 
after administration of a 14C labeled oral dose in a second period 
of the study utilizing liquid scintillation counting to determine 14C 
recovery from excreta. Metabolite profiling and identification is also 
performed from the samples collected at this part of the study.
Results: A variety of study designs and summary data from com-
pleted studies will be reviewed, and the benefits and merits of the 
design over conventional approaches to generate such data will be 
discussed. This will include evaluation of time and dose-dependent 
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nonlinear PK, DDI related changes in clearance, and absolute bio-
availability/mass balance data.
Conclusion: This integrated study design is a highly efficient mecha-
nism for generating definitive intravenous pharmacokinetic, clear-
ance, absolute bioavailability, mass balance, and human metabolism 
data from a single radiolabeled clinical protocol.
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Introduction: In recent years, improvement efforts have been geared 
toward activating clinical research performed in Japan. However, 
objectives of clinical research and trials are often unclear to the 
general public, given the difficulty in obtaining appropriate infor-
mation. To gain access to appropriate information about clinical 
research and trials, the general public needs information tools that 
are easy to use, as well as a basic knowledge about clinical research 
and trials. Building an efficient and easy-to-use portal site for patients 
and citizens is a major component of the new “5-year Clinical Trial 
Activation Plan (2012).” The present study aimed to investigate the 
type of information required and the kind of portal site considered 
useful by the general public based on a questionnaire survey.
Patients (or Materials) and Methods: Subjects of this study included 
500 Internet users aged ≥ 20 years. We used an Internet research 
method. The period of internet research from December 10, 2012, 
to December 20, 2012.The survey questionnaire mainly consisted of 
the following 3 parts:
1.  What kind of information do you want to obtain from a “clini-
cal research (trials) information site”?
2.  Ideas and wishes helpful for improving the information site 
(free-style questions)
3.  What kind of tools do you find easy to use when accessing the 
information site?
This study was carried out as part of the study funded by Grant-
in-Aid for Scientific Research of Health, Labour and Welfare in 
2012 FY. The study protocol was approved by the Kitasato Institute 
Hospital Research Ethics Committee.
Results: 1. The clinical research information which they considered 
highly necessary were “purpose,” “method,” “risks by participat-
ing,” “compensation if there is a health hazard,” “inconvenience or 
danger,” “cost,” and “period.”
2. Survey results showed that a site that allows the user to quickly 
extract only what is relevant to him/her was desired (eg, “I can search 
if I put the name of disease and symptoms,” “I want to be able to 
search by region,””Iwant a visualfriendly site”), in addition to “ease 
of access,” “explicit basis of reliability,” and “use of plain vocabulary.”
3. More than 90% responded that they use a personal computer 
(PC) at home to access the Internet. Use of a smartphone was < 30%, 
with the percentage being higher in younger respondents than older 
respondents. While > 60% of people used a PC for a longer time 
period than they used a smartphone, people in their 20s and 30s 
used a smartphone longer. While use of the social networking site 
(SNS) has spread recently, as a whole, it remained at 9.8%, except 
in the 20s (30%).
Conclusion: While building a web portal as a means to provide 
appropriate information is necessary, it is also important to increase 
the basic knowledge of clinical research and trials in the general pub-
lic so that they can determine the appropriateness of the information 
available to them.
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Introduction: The treatment modalities of ucerative colitis is an 
unmate need. The present study aims to evaluate efficacy of piogl-
itazone in mild to moderate ulcerative colitis patients compared with 
placebo. Previous studies were reportedly done on rosiglitazone, 
and this is foremost study to evaluate the efficacy of pioglitazone in 
ulcerative colitis patients.
Patients (or Materials) and Methods: Total 32 patients were seen 
in the study. It was a randomized, double-blind, placebo-controlled 
clinical trial compared the efficacy of pioglitazone 15 mg or placebo 
orally twice daily for 8 weeks in patients with mild to moderate active 
ulcerative colitis. The first group received 15-mg pioglitazone 2 times 
daily along with mesalamine. Second group received mesalamine plus 
similar looking placebo. The patients were followed up to 8 weeks, 
response to treatment was assessed clinically by Mayo clinical scor-
ing systems. Sigmoidoscopy was done at baseline and at 8 weeks of 
completion of treatment.
Results: Five patients were treated with pioglitazone and 4 patients were 
treated with placebo, completed therapy and achieved primary outcome. 
Gastrointestinal quality of life scores showed significant improvement 
in pioglitazone score compared with placebo group (0.03). Among the 
secondary efficacy end points, therapy with pioglitazone group lead to 
decrease in stool frequency, consistency, blood in stools, and abdominal 
pain. In placebo group the stool frequency decreased from (4.8 [3] to 
2 [1]) at the end of 8 weeks though the stool frequency was higher in 
placebo group initially. During the study, pioglitazone showed edema 
and weight gain and in placebo group, nausea, vomiting, abdominal 
pain, and diarrhea were most commonly observed.
Conclusion: The present double-blinded, placebo-controlled study 
with 8 weeks therapy of pioglitazone was not found superior to 
placebo for induction of clinical response in patients with ulcerative 
colitis.
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Introduction: While bariatric surgery (BS) to combat obesity con-
fers risks, it can also result in remission of diabetes mellitus (DM). 
Clinicians managing such patients should appreciate the relative and 
absolute extents of the latter effect. We therefore set out to derive 
unadjusted values for the relative chance (RC) and number needed 
to treat (NNT) for such an effect.
Patients (or Materials) and Methods: Two recently published, non-
blinded, randomized clinical trials compared DM remission rates 
